Budget impact of prophylactic treatment of rVIII-SingleChain in moderate and severe hemophilia A in Italy.
J Med Econ
; 26(1): 554-564, 2023.
Article
em En
| MEDLINE
| ID: mdl-37039544
Why was the study done? Hemophilia A is a rare inherited bleeding disorder. People with severe hemophilia are more likely to bleed compared to people without hemophilia and bleeds can occur spontaneously or in response to trauma. Patients are treated with medication to reduce the chance of bleeding. However, the cost of treating patients with hemophilia can be high and place demands on the healthcare system.What did we do and find?This study looked at the cost of treating people with hemophilia in Italy and used a type of economic analysis (called budget impact modelling) to estimate the effect of increasing the use of a particular medication (rVIII-SingleChain), compared to other medications that are available. Different variations of the model were tested to compare a range of scenarios.The results of this analysis suggested that increasing the use of rVIII-SingleChain may lead to cost-savings for the Italian healthcare system, compared to using the other currently available treatments. This analysis suggests that the use of rVIII-SingleChain enables people with hemophilia A to remain protected from bleeds, whilst using less product compared to other available medications.What is the influence of this study on the wider field?This type of analysis can be useful to healthcare systems, to guide the decision-making process regarding which medications to use or when making decisions related to healthcare policy.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Fator VIII
/
Hemofilia A
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article